principles to create treatments intended for easier administration compared to cell-based therapies.

The organization advances a pipeline of bispecific and trispecific antibody candidates that bind to multiple immune cell targets, enabling selective immune responses. These drug candidates are studied across various autoimmune conditions, with some programs progressing through early clinical evaluation.

Candid Therapeutics also conducts discovery and development activities aimed at improving depth and durability of immune modulation while managing safety considerations associated with immune activation.